Rey, which uses VR-based tools powered by OxfordVR to provide on-demand mental health care services, raises $26M Series A, three months after launching
Rashi Shrivastava / Forbes :
Context & Ripple Effects
Rey's $26M Series A lands three months after launch, and the round is really a bet on licensed infrastructure rather than new science: the service runs on VR simulations from OxfordVR, the Oxford University psychiatry spinout that raised its own £10M Series A last year to build VR treatments. AppliedVR already showed the funding appetite for this category with its $29M round for VR-based chronic pain therapeutics earlier in 2021 — Rey extends the pattern from single-condition clinics to on-demand mental health delivery.
First-order effects
- Rey gets runway to scale an on-demand service whose core therapeutic content it does not own — OxfordVR supplies the VR tools, making Rey a distribution layer rather than a developer.
Second-order effects
- OxfordVR gains proof that its technology can be monetized through partner platforms, not only direct-to-clinic sales, while non-VR rivals like Real, whose $37M Series B funded a $13/month subscription app, now compete against a modality that markets itself as clinically distinct rather than another meditation-style product.
Third-order effects
- Mental health care is splitting into modality-specific venture tracks — VR therapeutics (AppliedVR, Rey), clinician telehealth (Iris Telehealth's $40M Series B), and low-cost subscriptions (Real) — each raising separately, which points toward consolidation pressure as payers and patients eventually choose among formats rather than brands.
The trend: VR therapeutics are moving from university spinouts building clinical simulations to consumer platforms that license those simulations and sell care on demand.